Danaher Corp

Danaher Corporation has expanded its board from 11 to 13 members by appointing Daniel Comas and Robert Hershberg, effective October 9, 2026, to strengthen its financial, scientific, and biopharmaceutical expertise. Comas brings over three decades of experience with Danaher, including serving as EVP and CFO, while Hershberg offers significant scientific and biopharmaceutical expertise from his leadership roles at HilleVax and Celgene. Additionally, Alan Spoon will retire from the board in 2027, and co-founders Steven and Mitchell Rales have waived their rights to 500,000 restricted stock units each.

Morgan Stanley has maintained its "Buy" rating and a USD 240.00 target for Danaher stock, following the company's second-quarter revenue of USD 6.26 billion. This target is 7.76% above Danaher's current Nasdaq price. Danaher is scheduled to report its third-quarter results on October 21, 2026, with analysts expecting continued revenue growth.

Danaher (DHR) has expanded its Board of Directors to thirteen members, appointing Daniel L. Comas and Dr. Robert M. Hershberg. Comas, a former CFO of Danaher, brings extensive institutional knowledge, while Dr. Hershberg, a biotech veteran, adds significant industry expertise. Concurrently, director Alan G. Spoon announced his retirement, and co-founders Steven M. Rales and Mitchell P. Rales waived substantial stock awards.

Danaher Corporation has expanded its Board of Directors to thirteen members by appointing Daniel L. Comas and Robert M. Hershberg, effective October 9, 2026. Simultaneously, co-founders Steven M. Rales and Mitchell P. Rales voluntarily waived restricted stock unit awards totaling 500,000 shares each without compensation. The company also announced the upcoming retirement of director Alan G. Spoon at the 2027 annual shareholders meeting.

Danaher Corporation (DHR) filed a Form 8-K announcing board changes and the waiver of Founder RSUs. The company appointed Daniel L. Comas and Robert M. Hershberg to its Board of Directors, increasing the board size to thirteen members, and Alan G. Spoon will retire at the 2027 annual meeting. Additionally, co-founders Steven M. Rales and Mitchell P. Rales waived their right to 500,000 restricted stock units each.

TD Cowen has raised its price target for Danaher Corporation (DHR) to $255 from $236. This update reflects a new analyst assessment for the company. Danaher Corporation specializes in diagnostic, life sciences, and biotechnology equipment.

Danaher Corporation has appointed Daniel L. Comas and Robert Hershberg to its board, expanding it to 13 directors, effective October 9, 2026. This move adds expertise in finance, corporate development, biotechnology, and clinical development. The company's stock was trading at EUR 198.38 on October 13, 2026, ahead of its third-quarter results announcement on October 21, 2026.

Danaher Corporation announced the appointment of two new directors, Daniel L. Comas and Robert Hershberg, M.D., Ph.D., to its board on October 9, expanding the board from 11 to 13 members. The company's stock was trading at EUR 198.93 in pre-market on October 13, 2026, and its third-quarter earnings call is scheduled for October 21, 2026. Hershberg was also appointed to the Science and Technology Committee.

Freenome's updated SimpleScreen CRC blood test shows improved sensitivity for advanced precancerous lesions, detecting 18.2% compared to 13.7% for the original test. The test also achieved 80.4% sensitivity for colorectal cancer with 90% specificity. These results will be presented at the American College of Gastroenterology (ACG) 2026 Annual Meeting.

Danaher Corporation has appointed Daniel L. Comas and Dr. Robert Hershberg to its Board of Directors, increasing the board size from 11 to 13 members. Dr. Hershberg will also join the Science and Technology Committee. This move aims to enhance Danaher's growth and innovation in life sciences and biotechnology with new financial, strategic, and scientific expertise.